Journey Medical Corp (DERM) FinancialsDERMJourney Medical Corp

Journey Medical Corp (DERM) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Emrosi, accounting for 39.2% of total sales, equivalent to $6.25M. Other significant revenue streams include Qbrexa and Accutane. Understanding this composition is critical for investors evaluating how DERM navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Journey Medical Corp maintains a gross margin of 61.58%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 2.46%, while the net margin is -1.69%. These profitability ratios, combined with a Return on Equity (ROE) of -23.77%, provide a clear picture of how effectively DERM converts its operational activities into shareholder value.

In the context of the broader market, DERM competes directly with industry leaders such as TARA and NGEN. With a market capitalization of $121.35M, it holds a significant position in the sector. When comparing efficiency, DERM's gross margin of 61.58% stands against TARA's N/A and NGEN's N/A. Such benchmarking helps identify whether Journey Medical Corp is trading at a premium or discount relative to its financial performance.

Journey Medical has shown a positive trend in revenue growth, with total revenue increasing from $16 million in Q1 2026 to $18.5 million in Q2 2026. The gross margin has improved to 61.58% in Q2 2026, indicating better profitability.